Cargando…

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in adults with moderate-to-severe uncontrolled asthma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piper, Edward, Brightling, Christopher, Niven, Robert, Oh, Chad, Faggioni, Raffaella, Poon, Kwai, She, Dewei, Kell, Chris, May, Richard D., Geba, Gregory P., Molfino, Nestor A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561510/ https://www.ncbi.nlm.nih.gov/pubmed/22743678 http://dx.doi.org/10.1183/09031936.00223411

Ejemplares similares

Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
por: Singh, Dave, et al.
Publicado: (2010)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
por: Merola, Joseph F., et al.
Publicado: (2023)

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
por: Molfino, Nestor A, et al.
Publicado: (2016)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma
por: Nakamura, Yutaka, et al.
Publicado: (2017)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
por: Silverberg, J.I., et al.
Publicado: (2021)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
por: Wollenberg, A., et al.
Publicado: (2020)

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry
por: Sweeney, Joan, et al.
Publicado: (2012)

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma
por: Carlsson, Mats, et al.
Publicado: (2019)

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma
por: Oh, Chad K, et al.
Publicado: (2013)

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
por: Gottlow, Mattis, et al.
Publicado: (2019)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
por: Kelly, Katherine A, et al.
Publicado: (2022)

Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
por: Heaney, Liam G, et al.
Publicado: (2010)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
por: Moennig, Eva, et al.
Publicado: (2022)

Smoking and Idiopathic Pulmonary Fibrosis
por: Oh, Chad K., et al.
Publicado: (2012)

Targeting TSLP in Asthma
por: Parnes, Jane R, et al.
Publicado: (2022)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
por: TOLLENAERE, Maxim A. X., et al.
Publicado: (2021)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
por: De Greef, Axel, et al.
Publicado: (2023)

Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
por: Zhao, Dan-Jie, et al.
Publicado: (2023)

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability
por: Newby, Chris, et al.
Publicado: (2014)

Computational modeling of the obstructive lung diseases asthma and COPD
por: Burrowes, Kelly Suzanne, et al.
Publicado: (2014)

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
por: Parker, Joseph M, et al.
Publicado: (2011)

Destination Airway: Tracking Granulocytes in Asthma
por: Brightling, Christopher E.
Publicado: (2014)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
por: Hanania, Nicola A, et al.
Publicado: (2015)

Genetic predisposition to accelerated decline of lung function in COPD
por: Molfino, Néstor A
Publicado: (2007)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

Human Lung Mast Cells: Therapeutic Implications in Asthma
por: Poto, Remo, et al.
Publicado: (2022)

Mechanistic modeling of a human IgG(4) monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG(4) in healthy volunteers
por: Wang, Bing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e7a3crfsntqv176rlkaaek99dp